The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Resistance to lorlatinib in ROS1 fusion-positive non-small cell lung cancer.
 
Jessica Jiyeong Lin
Honoraria - OncLive; Pfizer
Consulting or Advisory Role - C4 Therapeutics; Genentech; Nuvalent, Inc.
Research Funding - Hengrui Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Ted Johnson
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Research Funding - Pfizer
Patents, Royalties, Other Intellectual Property - Inventor on Lorbrena (lorlatinib) patent (WO2013132376)
 
Jochen K Lennerz
No Relationships to Disclose
 
Charlotte Lee
No Relationships to Disclose
 
Harper Grace Hubbeling
No Relationships to Disclose
 
Beow Y. Yeap
Consulting or Advisory Role - Abcodia (I)
 
Ibiayi Dagogo-Jack
Honoraria - Foundation Medicine
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Array BioPharma (Inst); Guardant Health (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Justin F. Gainor
Employment - Ironwood Pharmaceuticals (I)
Stock and Other Ownership Interests - Ironwood Pharmaceuticals (I)
Honoraria - ARIAD; Incyte; Merck; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Agios; Amgen; Array BioPharma; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Gilead Sciences; Jounce Therapeutics; Lilly; Loxo; Merck; Moderna Therapeutics; Oncorus; Regeneron; Takeda; Theravance
Research Funding - Adaptimmune (Inst); Alexo Therapeutics (Inst); ARIAD; Array BioPharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Tesaro (Inst)
 
Alice Tsang Shaw
Employment - Novartis Institutes for BioMedical Research
Leadership - Syros Pharmaceuticals
Stock and Other Ownership Interests - Novartis Institutes for BioMedical Research
Honoraria - Foundation medicine; Guardant Health; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Achilles Therapeutics; ARIAD; Bayer; Blueprint Medicines; Chugai Pharma; Daiichi Sankyo; EMD Serono; Genentech; Ignyta; KSQ Therapeutics; Loxo; Natera; Novartis; Pfizer; Roche; Taiho Pharmaceutical; Takeda
Research Funding - ARIAD (Inst); Daiichi Sankyo (Inst); Ignyta (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); TP Therapeutics (Inst)